Parkway Cardiology Associates

Myocardial Infarction

Infarction

Coronary Disease

Drug-Related Side Effects and Adverse Reactions

Carotid Artery Diseases

Heart Diseases

Heart Failure

Vascular Diseases

Coronary Artery Disease

Myocardial Ischemia

Evolocumab

EVOLocumab

Empagliflozin

Amgen

Boehringer Ingelheim

Renaissance Pharma

University of Montreal

condition

Cardiovascular Diseases

allSponsorName

Colorado Prevention Center Clinical Research

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction \[NSTEMI\] and ST-segment elevation myocardial infarction \[STEMI\]).

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

Parkway Cardiology Associates | Parkway Cardiology Associates

Site insights

Work at this site?

Active trials

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

Trial sponsors